Free Trial
→ Top Picks for Trump’s Pro-Crypto America (From Crypto 101 Media) (Ad) Buy ELVN Stock  Free ELVN Stock Alerts

Enliven Therapeutics (ELVN) Financials

Enliven Therapeutics logo
$23.09 +1.18 (+5.39%)
Closing price 04:00 PM Eastern
Extended Trading
$23.08 -0.01 (-0.04%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Enliven Therapeutics

Annual Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -23 -49 -51 -38 -72 -89
Consolidated Net Income / (Loss)		 -23 -41 -51 -38 -72 -89
Net Income / (Loss) Continuing Operations		 -23 -41 -51 -38 -72 -89
Total Pre-Tax Income 		-23 -41 -51 -38 -72 -89
Total Operating Income		 -24 -42 -51 -39 -84 -105
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 24 42 51 39 84 105
Selling, General & Admin Expense		 5.11 9.54 13 7.77 19 24
Research & Development Expense		 19 32 38 31 65 81
Total Other Income / (Expense), net		 0.65 0.34 0.06 1.13 12 16
Interest & Investment Income		 0.58 0.48 0.23 1.13 12 15
Other Income / (Expense), net		 0.08 -0.15 -0.18 0.00 -0.02 0.87
Income Tax Expense		 - - 0.00 - 0.00 0.23
Basic Earnings per Share		 ($33.40) ($49,218,003.53) ($2.37) ($12.05) ($2.01) ($1.89)
Weighted Average Basic Shares Outstanding		 702.46K 13.92M 21.66M 3.12M 35.55M 47.07M
Diluted Earnings per Share		 ($33.40) ($49,218,003.53) ($2.37) ($12.05) ($2.01) ($1.89)
Weighted Average Diluted Shares Outstanding		 702.46K 13.92M 21.66M 3.12M 35.55M 47.07M
Weighted Average Basic & Diluted Shares Outstanding		 702.46K 13.92M 21.66M 26.23M 41.35M 49.00M

Quarterly Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -11 -9.55 -15 -17 -21 -19 -23 -20 -23 -23
Consolidated Net Income / (Loss)		 -11 -9.55 -15 -17 -21 -19 -23 -20 -23 -23
Net Income / (Loss) Continuing Operations		 -11 -9.55 -15 -17 -21 -19 -23 -20 -23 -23
Total Pre-Tax Income 		-11 -9.55 -15 -17 -21 -19 -23 -20 -23 -23
Total Operating Income		 -11 -10 -16 -20 -24 -23 -26 -25 -27 -27
Total Operating Expenses		 11 10 16 20 24 23 26 25 27 27
Selling, General & Admin Expense		 3.11 1.97 4.54 4.95 4.64 4.82 6.02 5.78 5.81 6.17
Research & Development Expense		 7.83 8.20 12 15 20 18 20 19 21 21
Total Other Income / (Expense), net		 0.38 0.61 1.69 3.41 3.48 3.36 3.25 4.89 3.91 3.48
Interest & Investment Income		 0.38 0.61 1.69 3.41 3.49 3.37 3.25 4.09 3.84 3.72
Basic Earnings per Share		 ($3.27) ($2.91) ($0.80) ($0.41) ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46)
Weighted Average Basic Shares Outstanding		 3.23M 3.12M 18.51M 40.96M 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M
Diluted Earnings per Share		 ($3.27) ($2.91) ($0.80) ($0.41) ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46)
Weighted Average Diluted Shares Outstanding		 3.23M 3.12M 18.51M 40.96M 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M
Weighted Average Basic & Diluted Shares Outstanding		 26.29M 26.23M 41.11M 41.15M 41.21M 41.35M 47.04M 47.24M 48.86M 49.00M

Annual Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -2.36 43 0.70 -34 25 24
Net Cash From Operating Activities		 -22 -37 -47 -32 -61 -73
Net Cash From Continuing Operating Activities		 -22 -37 -47 -32 -61 -73
Net Income / (Loss) Continuing Operations		 -23 -41 -51 -38 -72 -89
Consolidated Net Income / (Loss)		 -23 -41 -51 -38 -72 -89
Depreciation Expense		 0.03 0.10 0.10 0.22 0.30 0.32
Amortization Expense		 -0.02 0.12 0.16 0.00 -4.60 0.42
Non-Cash Adjustments To Reconcile Net Income		 0.90 2.23 3.87 4.93 13 20
Changes in Operating Assets and Liabilities, net		 0.67 1.51 0.51 0.44 1.40 -4.54
Net Cash From Investing Activities		 -24 -17 -1.63 -0.61 -148 -36
Net Cash From Continuing Investing Activities		 -24 -17 -1.63 -0.61 -148 -36
Purchase of Property, Plant & Equipment		 -0.14 -0.02 -0.01 -0.61 -0.15 -0.04
Purchase of Investments		 -24 -64 -48 0.00 -268 -351
Sale and/or Maturity of Investments		 0.00 48 46 0.00 120 314
Other Investing Activities, net		 - - - - 0.00 0.87
Net Cash From Financing Activities		 44 97 49 -1.80 234 133
Net Cash From Continuing Financing Activities		 44 97 49 -1.80 235 133
Payment of Dividends		 - - - 0.00 -8.74 0.00
Issuance of Common Equity		 0.00 80 1.82 0.00 161 130
Other Financing Activities, net		 0.00 1.02 0.86 -1.80 82 3.63
Cash Income Taxes Paid		 - - - - 0.00 0.23

Quarterly Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -6.30 -11 217 -166 -52 26 49 -52 3.75 23
Net Cash From Operating Activities		 -6.45 -8.15 -21 -12 -16 -12 -23 -20 -12 -17
Net Cash From Continuing Operating Activities		 -6.45 -8.15 -21 -12 -16 -12 -23 -20 -12 -17
Net Income / (Loss) Continuing Operations		 -11 -9.55 -15 -17 -21 -19 -23 -20 -23 -23
Consolidated Net Income / (Loss)		 -11 -9.55 -15 -17 -21 -19 -23 -20 -23 -23
Depreciation Expense		 0.06 0.06 0.07 0.07 0.08 0.08 0.08 0.08 0.08 0.08
Amortization Expense		 - - 0.00 -0.83 -1.98 -1.79 -0.66 -0.60 0.71 0.98
Non-Cash Adjustments To Reconcile Net Income		 2.84 0.74 2.26 4.20 3.63 3.13 4.59 4.42 5.18 5.43
Changes in Operating Assets and Liabilities, net		 1.21 0.61 -8.45 1.23 3.15 5.46 -4.64 -4.38 4.99 -0.51
Net Cash From Investing Activities		 -0.01 -0.10 -0.03 -152 -36 39 -18 -34 15 0.73
Net Cash From Continuing Investing Activities		 -0.01 -0.10 -0.03 -152 -36 39 -18 -34 15 0.73
Purchase of Investments		 - - 0.00 -151 -76 -41 -57 -121 -57 -117
Sale and/or Maturity of Investments		 - - 0.00 - 40 80 39 77 81 117
Net Cash From Financing Activities		 0.16 -2.38 237 -2.82 -0.43 0.09 90 1.81 1.12 40
Net Cash From Continuing Financing Activities		 0.16 -2.38 237 -2.82 -0.43 0.65 90 1.81 1.12 40
Issuance of Common Equity		 - - 163 -1.54 - - 90 0.02 - 40
Other Financing Activities, net		 0.16 -2.38 82 0.03 -0.43 0.65 0.27 1.79 1.12 0.45

Annual Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 33 91 94 83 272 326
Total Current Assets		 31 90 93 78 266 318
Cash & Equivalents		 4.94 48 48 76 100 124
Restricted Cash		 - - - 0.00 0.05 0.05
Short-Term Investments		 24 41 42 0.00 153 189
Prepaid Expenses		 1.72 2.18 2.42 2.22 2.95 4.63
Other Current Assets		 - - - 0.00 10 0.00
Plant, Property, & Equipment, net		 0.44 0.35 0.25 0.89 0.74 0.46
Total Noncurrent Assets		 2.23 0.09 0.70 4.66 4.97 7.18
Other Noncurrent Operating Assets		 2.23 0.09 0.70 4.66 4.97 7.18
Total Liabilities & Shareholders' Equity		 33 91 94 83 272 326
Total Liabilities		 4.38 6.41 7.62 10 26 16
Total Current Liabilities		 4.20 6.25 7.21 9.72 26 16
Accounts Payable		 1.66 1.97 2.36 3.44 0.53 1.34
Accrued Expenses		 2.54 4.28 4.60 6.28 15 15
Other Current Liabilities		 - 0.00 0.25 0.00 10 0.00
Total Noncurrent Liabilities		 0.18 0.16 0.41 0.66 0.07 0.00
Other Noncurrent Operating Liabilities		 - 0.00 0.41 0.66 0.07 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 84 86 73 246 310
Total Preferred & Common Equity		 -49 84 86 -77 246 310
Preferred Stock		 0.00 0.00 0.00 150 0.00 0.00
Total Common Equity		 -49 84 86 -77 246 310
Common Stock		 5.87 181 234 6.04 400 553
Retained Earnings		 -55 -96 -147 -83 -154 -243
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.00 -0.02 0.00 0.14 0.06

Quarterly Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 59 303 289 274 343 327 305
Total Current Assets		 59 298 283 269 337 318 297
Cash & Equivalents		 49 292 126 74 149 97 101
Restricted Cash		 - - - - 0.05 0.05 0.05
Short-Term Investments		 6.81 - 152 190 171 216 191
Prepaid Expenses		 2.80 5.90 5.31 5.13 6.64 5.68 5.11
Other Current Assets		 0.00 - - - 10 0.00 0.00
Plant, Property, & Equipment, net		 0.00 0.85 0.87 0.81 0.68 0.63 0.55
Total Noncurrent Assets		 0.00 4.01 4.46 4.63 4.90 8.29 7.88
Other Noncurrent Operating Assets		 0.00 4.01 4.46 4.63 4.90 8.29 7.88
Total Liabilities & Shareholders' Equity		 59 303 289 274 343 327 305
Total Liabilities		 1.82 11 9.51 12 25 22 17
Total Current Liabilities		 1.82 11 9.15 12 25 22 17
Accounts Payable		 0.77 5.86 2.84 1.49 2.73 1.08 1.02
Accrued Expenses		 1.05 5.08 6.30 11 12 12 16
Other Current Liabilities		 0.00 - - - 10 9.20 0.00
Total Noncurrent Liabilities		 0.00 0.51 0.36 0.21 0.03 0.01 0.00
Other Noncurrent Operating Liabilities		 0.00 0.51 0.36 0.21 0.03 0.01 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 57 291 279 262 318 305 288
Total Preferred & Common Equity		 57 291 279 262 318 305 288
Preferred Stock		 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 57 291 279 262 318 305 288
Common Stock		 235 389 393 397 495 502 508
Retained Earnings		 -178 -98 -114 -135 -177 -197 -220
Accumulated Other Comprehensive Income / (Loss)		 -0.00 - -0.11 -0.15 -0.05 -0.14 0.24

Annual Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -73.24% -23.40% 24.90% -127.75% -17.17%
EBIT Growth		 0.00% -74.05% -23.36% 24.85% -115.39% -24.10%
NOPAT Growth		 0.00% -72.91% -23.37% 24.59% -115.33% -25.17%
Net Income Growth		 0.00% -76.28% -24.24% 26.70% -90.07% -24.36%
EPS Growth		 0.00% -147,359,192.01% 100.00% -408.44% 83.32% 5.97%
Operating Cash Flow Growth		 0.00% -70.95% -25.06% 31.42% -91.01% -19.46%
Free Cash Flow Firm Growth		 0.00% 0.00% -40.00% 19.01% -86.82% -42.85%
Invested Capital Growth		 0.00% -42,177.78% -12.17% 38.51% -179.33% 49.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -66.62% 9.73% -19.54% -1.37%
EBIT Q/Q Growth		 0.00% 0.00% -65.41% 9.71% -17.74% -4.18%
NOPAT Q/Q Growth		 0.00% 0.00% -65.92% 9.71% -17.71% -4.15%
Net Income Q/Q Growth		 0.00% 0.00% -5.77% 11.24% -15.90% -4.47%
EPS Q/Q Growth		 0.00% 0.00% 100.00% -100.00% 56.59% -9.88%
Operating Cash Flow Q/Q Growth		 0.00% -0.61% -9.91% 11.92% -7.62% -6.89%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 16.60% -14.53% -12.14%
Invested Capital Q/Q Growth		 0.00% 0.00% -22.56% -365.99% -321.73% -4.71%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.26%
Interest Burden Percent		 97.60% 98.85% 99.55% 97.09% 85.68% 85.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -81.14% -72.98% -60.29% -47.39% -44.90% -32.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 137.07% -22.91% -60.29% -2.74% -23.81% -32.04%
Return on Equity Simple (ROE_SIMPLE)		 48.03% -48.98% -59.73% 49.02% -29.11% -28.73%
Net Operating Profit after Tax (NOPAT)		 -17 -29 -36 -27 -58 -73
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -22.77% -20.78% -17.23% -12.67% -7.98% -5.59%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -23.78% -23.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -24 -42 -52 -39 -84 -104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -42 -51 -39 -88 -103
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 4.55 0.69 0.00 2.32 3.55
Price to Tangible Book Value (P/TBV)		 0.00 4.55 0.69 0.00 2.32 3.55
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 13,834.11 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.03 -1.05 -1.04 -1.03 -1.02
Leverage Ratio		 1.15 1.10 1.08 1.11 1.11 1.08
Compound Leverage Factor		 1.12 1.08 1.08 1.08 0.95 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 205.35% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 268.93% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -168.93% 100.00% 100.00% -105.35% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.63 34.06 1.73 4.27 12.43 40.46
Noncontrolling Interest Sharing Ratio		 268.93% 68.60% 0.00% 94.21% 46.97% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 7.29 14.47 12.86 8.00 10.28 19.99
Quick Ratio		 6.89 14.12 12.52 7.78 9.78 19.69
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -36 -29 -54 -77
Operating Cash Flow to CapEx		 -15,626.43% -207,766.67% -389,758.33% -5,241.34% -41,120.13% -166,345.45%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.01 -3.79 -4.25 -2.61 -7.30 -3.65
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -3.80 -0.46 1.64 -4.68 3.65
Enterprise Value (EV)		 125 296 -31 182 317 786
Market Capitalization		 76 384 59 108 570 1,099
Book Value per Share		 ($69.54) $4.85 $3.27 ($2.92) $5.97 $6.34
Tangible Book Value per Share		 ($69.54) $4.85 $3.27 ($2.92) $5.97 $6.34
Total Capital		 29 84 86 73 246 310
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -29 -88 -90 -76 -253 -313
Capital Expenditures (CapEx)		 0.14 0.02 0.01 0.61 0.15 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.48 -4.06 -4.79 -7.50 -13 -11
Debt-free Net Working Capital (DFNWC)		 26 84 85 68 240 302
Net Working Capital (NWC)		 26 84 85 68 240 302
Net Nonoperating Expense (NNE)		 6.58 12 15 11 13 16
Net Nonoperating Obligations (NNO)		 -29 -88 -90 -76 -253 -313
Total Depreciation and Amortization (D&A)		 0.01 0.22 0.25 0.22 -4.31 0.74
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.06 ($2.01) ($1.89)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 17.58M 26.29M 26.29M 35.55M 47.07M
Adjusted Diluted Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.06 ($2.01) ($1.89)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.58M 26.29M 26.39M 35.55M 47.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.53) ($51,384,002.37) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.92M 21.66M 26.23M 41.35M 49.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -29 -36 -27 -58 -73
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -12.20% 0.00%
Augmented Payout Ratio		 -8.51% -4.15% -1.12% 0.00% -12.20% 0.00%

Quarterly Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 20.26% 29.45% -89.27% -133.05% -140.64% -142.08% -62.50% -16.46% -0.14% -5.69%
EBIT Growth		 20.06% 29.38% -89.19% -123.31% -121.89% -123.73% -58.29% -18.23% -11.27% -18.29%
NOPAT Growth		 19.95% 29.10% -89.19% -123.31% -121.77% -123.64% -58.28% -22.20% -11.63% -18.33%
Net Income Growth		 22.66% 33.31% -69.85% -88.11% -96.79% -102.83% -54.43% -19.31% -11.49% -19.67%
EPS Growth		 -341.89% -100.00% 73.42% 85.66% 84.40% 90.03% 32.50% 0.00% 5.88% -58.62%
Operating Cash Flow Growth		 40.86% 34.76% -101.18% -69.13% -146.53% -53.25% -12.08% -69.60% 23.29% -37.82%
Free Cash Flow Firm Growth		 -61.65% 8.59% -102.25% -55.41% -17.85% -28.30% -41.93% 39.56% -20.55% -100.19%
Invested Capital Growth		 128.33% 38.51% -40.57% 10.25% -276.17% -179.33% -314.87% -765.37% -101.45% 49.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -21.31% 7.13% -61.91% -27.77% -25.25% 6.57% -8.68% 8.43% -7.70% 1.39%
EBIT Q/Q Growth		 -21.27% 7.05% -61.55% -22.63% -20.50% 6.28% -14.29% 8.40% -13.41% 0.37%
NOPAT Q/Q Growth		 -21.27% 7.05% -61.55% -22.63% -20.43% 6.26% -14.33% 5.33% -10.02% 0.64%
Net Income Q/Q Growth		 -18.73% 9.51% -54.18% -13.56% -24.21% 6.74% -17.39% 12.26% -16.07% -0.10%
EPS Q/Q Growth		 -14.34% 11.01% 72.51% 48.75% -24.39% 43.14% -86.21% 24.07% -17.07% 4.17%
Operating Cash Flow Q/Q Growth		 9.50% -26.34% -155.91% 42.19% -31.91% 21.47% -87.16% 12.53% 40.33% -41.09%
Free Cash Flow Firm Q/Q Growth		 -32.46% 27.70% -29.08% -25.71% -0.44% 21.28% -42.80% 46.47% -100.35% -30.72%
Invested Capital Q/Q Growth		 -4.10% -365.99% 73.74% 264.58% -253.23% -321.73% 60.99% -163.95% 53.61% -4.71%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 101.18% 100.00% 100.00%
Interest Burden Percent		 96.52% 93.97% 89.68% 83.05% 85.61% 85.19% 87.49% 82.83% 85.78% 86.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.17% -47.39% -24.03% -30.29% -38.72% -44.90% -26.14% -28.37% -30.98% -32.04%
Cash Return on Invested Capital (CROIC)		 -3,515.42% 0.00% 0.00% -3,758.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.17% -2.74% -24.03% -30.29% -38.72% -23.81% -26.14% -28.37% -30.98% -32.04%
Return on Equity Simple (ROE_SIMPLE)		 -74.07% 0.00% -15.00% -18.48% -23.60% 0.00% -25.05% -27.16% -29.55% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.65 -7.11 -11 -14 -17 -16 -18 -17 -19 -19
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.64% -2.94% -1.77% -1.55% -2.37% -2.10% -1.48% -0.92% -1.52% -1.54%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -6.47% - - - -6.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -10 -16 -20 -24 -23 -26 -24 -27 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -10 -16 -21 -26 -24 -27 -24 -26 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.05 0.00 1.97 3.01 2.15 2.32 2.29 3.60 4.18 3.55
Price to Tangible Book Value (P/TBV)		 1.05 0.00 1.97 3.01 2.15 2.32 2.29 3.60 4.18 3.55
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.70 0.00 0.00 497.16 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.00 -0.99 -1.00 -1.03 -1.01 -1.01 -1.01 -1.02
Leverage Ratio		 1.06 1.11 1.06 1.04 1.04 1.11 1.06 1.05 1.05 1.08
Compound Leverage Factor		 1.02 1.05 0.95 0.86 0.89 0.95 0.93 0.87 0.90 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 205.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% -105.35% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.11 5.40 30.61 53.31 27.58 13.17 17.53 29.83 42.31 41.24
Noncontrolling Interest Sharing Ratio		 0.00% 94.21% 0.00% 0.00% 0.00% 46.97% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 32.51 8.00 27.23 30.96 22.24 10.28 13.47 14.39 17.44 19.99
Quick Ratio		 30.97 7.78 26.70 30.38 21.81 9.78 12.80 14.13 17.14 19.69
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12 -8.75 -11 -14 -14 -11 -16 -8.58 -17 -22
Operating Cash Flow to CapEx		 -46,050.00% -8,064.36% -67,238.71% -13,692.05% -99,337.50% -89,157.14% -116,805.00% -1,021,750.00% -55,422.73% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.98 -2.61 -0.69 1.13 -1.73 -7.30 -2.85 -7.51 -3.49 -3.65
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.45 1.64 -0.20 0.11 -2.71 -4.68 -2.16 -8.64 -1.76 3.65
Enterprise Value (EV)		 3.63 182 282 561 299 317 407 787 915 786
Market Capitalization		 60 108 575 839 562 570 727 1,099 1,206 1,099
Book Value per Share		 $2.18 ($2.92) $11.11 $6.79 $6.36 $5.97 $7.68 $6.48 $6.11 $6.34
Tangible Book Value per Share		 $2.18 ($2.92) $11.11 $6.79 $6.36 $5.97 $7.68 $6.48 $6.11 $6.34
Total Capital		 57 73 291 279 262 246 318 305 288 310
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -56 -76 -292 -278 -263 -253 -321 -312 -292 -313
Capital Expenditures (CapEx)		 0.01 0.10 0.03 0.09 0.02 0.01 0.02 0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.98 -7.50 -5.04 -3.84 -6.95 -13 -8.39 -16 -12 -11
Debt-free Net Working Capital (DFNWC)		 57 68 287 274 257 240 312 296 280 302
Net Working Capital (NWC)		 57 68 287 274 257 240 312 296 280 302
Net Nonoperating Expense (NNE)		 2.90 2.44 3.23 2.63 3.80 3.46 4.55 2.73 4.21 4.35
Net Nonoperating Obligations (NNO)		 -56 -76 -292 -278 -263 -253 -321 -312 -292 -313
Total Depreciation and Amortization (D&A)		 0.06 0.06 0.07 -0.76 -1.91 -1.71 -0.58 -0.53 0.79 1.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.18) ($2.91) ($0.80) ($0.41) ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 26.29M 3.12M 18.51M 40.96M 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M
Adjusted Diluted Earnings per Share		 ($0.44) ($2.91) ($0.80) ($0.41) ($0.51) ($0.29) ($0.54) ($0.41) ($0.48) ($0.46)
Adjusted Weighted Average Diluted Shares Outstanding		 26.29M 3.12M 18.51M 40.96M 41.03M 35.55M 42.05M 48.08M 48.27M 47.07M
Adjusted Basic & Diluted Earnings per Share		 ($4,609,000.00) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 26.29M 26.23M 41.11M 41.15M 41.21M 41.35M 47.04M 47.24M 48.86M 49.00M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.65 -7.11 -11 -14 -17 -16 -18 -17 -19 -19
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% -16.97% -16.95% -14.14% -12.20% -1.65% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -16.97% -16.95% -14.14% -12.20% -1.65% 0.00% 0.00% 0.00%

Frequently Asked Questions About Enliven Therapeutics' Financials

When does Enliven Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Enliven Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Enliven Therapeutics' net income changed over the last 5 years?

Enliven Therapeutics' net income appears to be on an upward trend, with a most recent value of -$89.02 million in 2024, rising from -$23.46 million in 2019. The previous period was -$71.58 million in 2023. See Enliven Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Enliven Therapeutics' operating income?
Enliven Therapeutics' total operating income in 2024 was -$104.55 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $104.55 million
How has Enliven Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Enliven Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Enliven Therapeutics have?

Enliven Therapeutics' total liabilities were at $15.92 million at the end of 2024, a 38.7% decrease from 2023, and a 263.2% increase since 2019.

How much cash does Enliven Therapeutics have?

In the past 5 years, Enliven Therapeutics' cash and equivalents has ranged from $4.94 million in 2019 to $124.12 million in 2024, and is currently $124.12 million as of their latest financial filing in 2024.

How has Enliven Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Enliven Therapeutics' book value per share changed from -69.54 in 2019 to 6.34 in 2024, a change of -109.1%.


Related Companies

This page (NASDAQ:ELVN) was last updated on 6/16/2025 by MarketBeat.com Staff
From Our Partners
When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Something Big Is Coming...
Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...
Stansberry Research | Sponsored
BREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"
This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...
American Alternative | Sponsored
The mainstream media is wrong about AI — again
The mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...
Weiss Ratings | Sponsored
Think you missed gold’s boom? Think again
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...
Investors Alley | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...
Brownstone Research | Sponsored